Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target.

Autor: Ferrari MG; Department of Urology, Rush University Medical Center, Chicago, IL, USA., Jimenez-Uribe AP; Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA., Wang L; The Hormel Institute, Masonic Cancer Center, University of Minnesota, Austin, MN, USA., Hoeppner LH; The Hormel Institute, Masonic Cancer Center, University of Minnesota, Austin, MN, USA., Murugan P; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA., Hahm E; Department of Internal Medicine, Rush University Medical Center, Chicago, IL, USA., Yu J; Department of Urology and Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA.; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Kuzel TM; Department of Internal Medicine, Division of Hematology, Oncology and Cell Therapy, Rush Medical College, Chicago, IL, USA., Gradilone SA; The Hormel Institute, University of Minnesota, Austin, MN, USA., Mansini AP; Department of Urology, Rush University Medical Center, Chicago, IL, USA. adrian_mansini@rush.edu.

Publikováno v: Oncogene [Oncogene] 2024 Feb; Vol. 43 (7), pp. 484-494. Date of Electronic Publication: 2023 Dec 23.